> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-76/
- Published: 2022-05-22T12:00:00.000Z
- Updated: 2026-09-14T17:45:29.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141226

**Shire** has agreed to sell its oncology business for $2.4 billion to **Servier**. The transaction includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and outside-the-U.S. rights to Onivyde (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes calaspargase pegol, which is under FDA review for treating ALL and early stage immuno-oncology pipeline collaborations. 

**Boston Scientific** has acquired for an undisclosed amount **nVision Medical**, a privately-held company focused on women’s health. nVision developed the first device cleared by FDA to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tube. 

**Alexion Pharmaceuticals** has agreed to buy Stockholm, Sweden-based **Wilson Therapeutics** for $855 million. The transaction will give Alexion rights to WTX101, Wilson Therapeutics’ Phase 3 compound for Wilson disease, a rare genetic disorder that affects copper transport and affects the liver.